Neuralink’s secondary-market marks have climbed sharply to around $52.9 billion as of early October 2026, reflecting a roughly 448 percent increase from the $9.7 billion post-money valuation established in its June 2025 Series E round. This repricing stems from sustained clinical-trial momentum, including October 2026 updates showing reduced calibration times for implant users and record information-transfer rates above 11 bits per second, alongside FDA breakthrough-device designation for the Blindsight vision-restoration implant. With total funding still below $1.4 billion and no IPO timeline disclosed, trader sentiment hinges on further trial readouts, potential additional secondary liquidity events, and any regulatory or competitive developments in the brain-computer interface sector before year-end resolution.